189 related articles for article (PubMed ID: 11205835)
1. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
Omilabu SA; Oyefolu AO; Ojo OO; Audu RA
Afr J Med Med Sci; 1999; 28(3-4):209-12. PubMed ID: 11205835
[TBL] [Abstract][Full Text] [Related]
2. Low seroconversion rates to measles vaccine among children in Nigeria.
Adu FD; Akinwolere OA; Tomori O; Uche LN
Bull World Health Organ; 1992; 70(4):457-60. PubMed ID: 1394778
[TBL] [Abstract][Full Text] [Related]
3. Measles HI-antibody levels in Lagos children, Nigeria: a follow-up study to resurgence of measles in Lagos metropolis.
Oyefolu AO; Omilabu SA
West Afr J Med; 2001; 20(3):238-42. PubMed ID: 11922159
[TBL] [Abstract][Full Text] [Related]
4. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.
Fowotade A; Okonko IO; Nwabuisi C; Bakare RA; Fadeyi A; Adu FD
J Immunoassay Immunochem; 2015; 36(2):195-209. PubMed ID: 24825255
[TBL] [Abstract][Full Text] [Related]
5. Study of antibody titres after measles vaccination: fever within 7 days of vaccination and efficacy of booster doses.
Egami T; Egami K; Tanoue A
Arch Dis Child; 2008 Apr; 93(4):319-20. PubMed ID: 17488762
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy evaluation of measles vaccine in fields].
Liu M
Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Oct; 12(5):292-4. PubMed ID: 1782660
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi.
Helfand RF; Witte D; Fowlkes A; Garcia P; Yang C; Fudzulani R; Walls L; Bae S; Strebel P; Broadhead R; Bellini WJ; Cutts F
J Infect Dis; 2008 Nov; 198(10):1457-65. PubMed ID: 18828743
[TBL] [Abstract][Full Text] [Related]
8. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia.
Viviani S; Mendy M; Jack AD; Hall AJ; Montesano R; Whittle HC
Trop Med Int Health; 2004 Oct; 9(10):1044-9. PubMed ID: 15482396
[TBL] [Abstract][Full Text] [Related]
9. Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.
Eghafona NO; Ahmad AA; Ezeokoli CD; Emejuaiwe SO
Microbios; 1991; 67(274):33-6. PubMed ID: 1758308
[TBL] [Abstract][Full Text] [Related]
10. Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.
Nkrumah FK; Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA
Bull World Health Organ; 1998; 76(4):353-9. PubMed ID: 9803586
[TBL] [Abstract][Full Text] [Related]
11. Optimal age for vaccinating Nigerian children against measles. I. Neonatal antibody profile and subsequent susceptibility to measles.
Harry TO; Ogunmekan DA
Trop Geogr Med; 1981 Dec; 33(4):375-8. PubMed ID: 7342384
[TBL] [Abstract][Full Text] [Related]
12. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
Ogunmekan DA; Harry TO
Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of three measles vaccines in Indian children.
Banerjee K; Shaikh N; Phadke M; Bedekar SS; Rauta SK; Mehta JM
Indian J Public Health; 1998; 42(4):113-9. PubMed ID: 10389523
[TBL] [Abstract][Full Text] [Related]
14. [The clinical evaluation and immunological response of a new measles vaccine].
Moretti P; Branciaroli A; Di Battista S; Di Filippo A; Di Pietro M; Calafiore P; Di Battista C
Minerva Pediatr; 1993 Mar; 45(3):83-6. PubMed ID: 8341231
[TBL] [Abstract][Full Text] [Related]
15. Immune responses to measles immunization and the impacts on HIV-infected children.
Thaithumyanon P; Punnahitananda S; Thisyakorn U; Praisuwanna P; Ruxrungtham K
Southeast Asian J Trop Med Public Health; 2000 Dec; 31(4):658-62. PubMed ID: 11414407
[TBL] [Abstract][Full Text] [Related]
16. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
[TBL] [Abstract][Full Text] [Related]
17. Field trial of combined yellow fever and measles vaccines among children in Nigeria.
Adu FD; Omotade OO; Oyedele OI; Ikusika O; Odemuyiwa SO; Onoja AL
East Afr Med J; 1996 Sep; 73(9):579-82. PubMed ID: 8991237
[TBL] [Abstract][Full Text] [Related]
18. Seroconversion after measles vaccination at nine and fifteen months of age.
Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
[TBL] [Abstract][Full Text] [Related]
19. Field evaluation of measles vaccine efficacy in New Seemapuri, Shahdara Zone-Delhi during 1990.
Chawla U; Benera SK; Bandyopadhyay S; Chaudhary BN; Gupta OP; Khallendra RK; Ramaswamy J; Khare S; Sharma RS; Dutta KK
J Commun Dis; 1990 Jun; 22(2):134-9. PubMed ID: 2098412
[TBL] [Abstract][Full Text] [Related]
20. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren.
Bennett JV; Fernandez de Castro J; Valdespino-Gomez JL; Garcia-Garcia Mde L; Islas-Romero R; Echaniz-Aviles G; Jimenez-Corona A; Sepulveda-Amor J
Bull World Health Organ; 2002; 80(10):806-12. PubMed ID: 12471401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
